BIVI: BioVie Inc Price-to-Revenue Ratio

Brandmark of BioVie Pharma (BIVI)

BioVie Inc. has long struggled for capital amid fierce competition in the development of treatments for Alzheimer's and liver pathologies. Historical P/S dynamics on GURU.Markets show that the indicator reaches . The company's prospects rely on the high margins of future patents and the implementation of energy-saving technologies in laboratories to comply with environmental regulations.

BioVie Inc. (BIVI): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Analytical breakdowns for BioVie Inc. (BIVI)

- share price and consensus valuation forecast:
Price Performance Chart biovieinc.com|BIVI - Analyst Consensus Forecast
- market capitalization information:
Market Value BioVie Pharma|BIVI - Enterprise Value
- issuer book value statistics:
Net Assets per Share BioVie|BIVI - Company Book Value|Market-to-Book Ratio biovieinc.com|BIVI - Cumulative Company Assets
- debt obligations and liquidity statistics:
Debt to Equity BioVie Inc.|BIVI - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient biovieinc.com|BIVI - Company Aggregate Debts|Debts to Book Value BioVie Pharma|BIVI - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings BioVie|Interim Coverage Ratio biovieinc.com
- net income and valuation ratios data:
BIVI - Company Net Income|Net Profit Forecast BioVie Inc.|BIVI - P/E Multiple|Projected Price to Earnings biovieinc.com|BIVI - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio BioVie Pharma|BIVI - Operating profit EBITDA|Earnings per share for the last twelve months BioVie|BIVI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biovieinc.com|BIVI - Net earnings per share growth this year|Net earnings per share growth forecast for next year BioVie Inc.
- total revenue and sales volume data:
BIVI - Revenue and Sales Volume|Company Future Sales biovieinc.com|BIVI - Price-to-Revenue Ratio|Future Price to Revenue BioVie Pharma
General company analysis:BIVI - BioVie Inc
Product sample of BioVie Inc

To qualitatively assess an asset, it is essential for an investor to compare the business's market value with its actual earnings. The P/S metric determines how many dollars of capitalization are attributed to each unit of revenue, revealing whether a company is overvalued or undervalued. By analyzing the capitalization-to-revenue ratio, investors can identify entry points and avoid overheated assets. For BioVie Inc. (BIVI), this indicator reflects market expectations regarding the commercialization of innovations and the success of clinical trials.

Who BioVie Inc. competes with

ARWR (arrowheadpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple MIRM (Mirum)|Dynavax Corp - Price-to-Revenue Ratio|Arbutus - P/S Multiple|Price-to-Revenue Coefficient Inventiva Corp IVA|Gyre Therapeutics, Inc. (GYRE) - Price-to-Revenue Ratio|Price to Sales assemblybio.com (ASMB)|Market Cap to Revenue GALT|Price-to-Revenue Ratio GNFT|P/S Multiple DRRX|Price-to-Revenue Coefficient aligos.com|P/S Multiple GLMD (Galmed Pharmaceuticals Ltd.)|endrainc.com (NDRA) - Price to Sales|HEPA: Market Cap to Revenue